KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:KYORIN Holdings Inc (4569) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12398
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over-the-counter (OTC) drugs. It also provides consumer healthcare products including beauty and good health products. KYORIN provides product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. KYORIN is headquartered in Chiyoda-Ku, Tokyo, Japan.

KYORIN Holdings Inc (4569) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kyorin Acquires Production Facility from MSD 11
Partnerships 12
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Licensing Agreements 23
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
KYORIN Rimedio Enters into a Licensing Agreement with Binh Dinh Pharma 24
Kyorin Pharma Enters into Licensing Agreement with Merck 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 27
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 28
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 29
Kyorin Pharma Enters into Licensing Agreement with Merck 30
Asset Transactions 31
Galderma Acquires Pekiron Cream From Kyorin Pharma 31
Acquisition 32
Taisho Pharma to Acquire Dr. Program from Kyorin Pharma 32
Teijin Acquires 10% Stake In Kyorin For US$197 Million 33
KYORIN Holdings Inc – Key Competitors 34
KYORIN Holdings Inc – Key Employees 35
KYORIN Holdings Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Other Significant Developments 37
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 37
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 8
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kyorin Acquires Production Facility from MSD 11
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
KYORIN Rimedio Enters into a Licensing Agreement with Binh Dinh Pharma 24
Kyorin Pharma Enters into Licensing Agreement with Merck 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 27
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 28
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 29
Kyorin Pharma Enters into Licensing Agreement with Merck 30
Galderma Acquires Pekiron Cream From Kyorin Pharma 31
Taisho Pharma to Acquire Dr. Program from Kyorin Pharma 32
Teijin Acquires 10% Stake In Kyorin For US$197 Million 33
KYORIN Holdings Inc, Key Competitors 34
KYORIN Holdings Inc, Key Employees 35
KYORIN Holdings Inc, Subsidiaries 36

List of Figures
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gamma Solutions SL:電力:M&Aディール及び事業提携情報
    Summary Gamma Solutions SL (Gamma Solutions) is an engineering and consulting company that operates through energy, telecommunication, mobile and IT, and research and development divisions. The company offers products such as gamma start city monitoring system, photovoltaic rooftop monitoring system …
  • Trina Solar Ltd:企業の戦略的SWOT分析
    Trina Solar Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Fives:企業の戦略・SWOT・財務情報
    Fives - Strategy, SWOT and Corporate Finance Report Summary Fives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • British Airways Plc:企業の戦略的SWOT分析
    British Airways Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • PrIME Biologics Pte Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary PrIME Biologics Pte Ltd (PrIME Biologics) is a biotechnology company that develops and manufactures plasma products for human use. The company uses Preparative Isolation by Membrane Electrophoresis ((PrIME) technology, a disposable, fully-scalable and modular manufacturing process, to manufa …
  • Sakai Chemical Industry Co Ltd (4078):企業の財務・戦略的SWOT分析
    Sakai Chemical Industry Co Ltd (4078) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Wagamama Limited :企業の戦略・SWOT・財務情報
    Wagamama Limited - Strategy, SWOT and Corporate Finance Report Summary Wagamama Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Les Laboratoires Servier:企業の戦略・SWOT・財務情報
    Les Laboratoires Servier - Strategy, SWOT and Corporate Finance Report Summary Les Laboratoires Servier - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Laboratoires Pierre Fabre SA:企業の戦略的SWOT分析
    Laboratoires Pierre Fabre SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Acura Pharmaceuticals Inc (ACUR)-医療機器分野:企業M&A・提携分析
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • M. A. Mortenson Company:企業の戦略・SWOT・財務情報
    M. A. Mortenson Company - Strategy, SWOT and Corporate Finance Report Summary M. A. Mortenson Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Qube Holdings Ltd:戦略・SWOT・企業財務分析
    Qube Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Qube Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析
    Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Caris Life Sciences Inc:企業の製品パイプライン分析
    Summary Caris Life Sciences Inc (Caris Life) is a biotechnology company. The company’s molecular scientific offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make personalized treatment decisions. Its ADAPT biotargeting system, is a plat …
  • Emmis Communications Corporation (EMMS):企業の財務・戦略的SWOT分析
    Emmis Communications Corporation (EMMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Santander Private Bank:企業の戦略・SWOT・財務情報
    Santander Private Bank - Strategy, SWOT and Corporate Finance Report Summary Santander Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company offers services such as marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data …
  • Bioverativ Inc (BIVV):医療機器:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Tencent Holdings Limited:企業のM&A・事業提携・投資動向
    Tencent Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tencent Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Welltower Inc:企業の戦略・SWOT・財務情報
    Welltower Inc - Strategy, SWOT and Corporate Finance Report Summary Welltower Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆